Abstract
Purpose
Dynamic susceptibility contrast (DSC) perfusion-weighted MR imaging (PWI) is increasingly used in clinical neuroimaging for a range of conditions. More highly concentrated GBCAs (e.g., gadobutrol) are often preferred for DSC imaging because it is thought that more Gd is present in the volume of interest during first pass for a given equivalent injection rate. However, faster injection of a less viscous GBCA (e.g., gadoteridol) might generate a more compact and narrower contrast bolus thus obviating any perceived benefit of higher Gd concentration. This preliminary study aimed to analyze and compare DSC examinations in the healthy brain hemisphere of patients with brain tumors using gadobutrol and gadoteridol administered at injection rates of 4 and 6 mL/s.
Methods
Thirty-nine brain tumor patients studied with DSC-PWI were evaluated. A simplified gamma-variate model function was applied to calculate the mean peak, area under the curve (AUC), and full-width at half-maximum (FHWM) of concentration–time curves derived from ΔR2* signals at four different regions-of-interest (ROIs). Qualitative assessment of the derived CBV maps was also performed independently by 2 neuroradiologists.
Results
No qualitative or quantitative differences between the two GBCAs were observed when administered at a flow rate of 4 mL/s. At a flow rate of 6 mL/s, gadoteridol showed lower FWHM values.
Conclusion
Gadobutrol and gadoteridol are equivalent for clinical assessment of qualitative CBV maps and quantitative perfusion parameters (FHWM) at a flow rate of 4 mL/s. At 6 mL/s, gadoteridol produces a narrower bolus shape and potentially improves quantitative assessment of perfusion parameters.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- DSC:
-
Dynamic susceptibility contrast
- PWI:
-
Perfusion-weighted imaging
- GBCA:
-
Gadolinium-based contrast agent
- AUC:
-
Area under the curve
- FWHM:
-
Full-width at half-maximum
References
Cha S (2003) Perfusion MR imaging: basic principles and clinical applications. Magn Reson Imaging Clin N Am 11:403–413. https://doi.org/10.1016/S1064-9689(03)00066-7
Aronen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41–51. https://doi.org/10.1148/radiology.191.1.8134596
Knopp EA, Cha S, Johnson G et al (1999) Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 211:791–798. https://doi.org/10.1148/radiology.211.3.r99jn46791
Caulo M, Panara V, Tortora D et al (2014) Data driven grading of brain gliomas: a multiparametric MRI study. Radiology 272:494–503. https://doi.org/10.1148/radiol.14132040
Santarosa C, Castellano A, Conte GM et al (2016) Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis. Eur J Radiol 85(6):1147–1156. https://doi.org/10.1016/j.ejrad.2016.03.020
Anzalone N, Castellano A, Cadioli M et al (2018) Brain gliomas: multicenter standardized assessment of dynamic contrast-enhanced and dynamic susceptibility contrast MR images. Radiology 287(3):933–943. https://doi.org/10.1148/radiol.2017170362
Schmainda KM, Zhang Z, Prah M et al (2015) Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol 17:1148–1156. https://doi.org/10.1093/neuonc/nou364
Rosen BR, Belliveau JW, Aronen HJ et al (1991) Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med 22:293–299. https://doi.org/10.1002/mrm.1910220227
Griffiths PD, Wilkinson ID, Wels T et al (2001) Brain MR perfusion imaging in humans: advantages of high-molarity gadolinium chelates. Acta Radiol 42:555–559
Heiland S, Erb G, Ziegler S, Krix M (2010) Where contrast agent concentration really matters – a comparison of CT and MRI. Invest Radiol 45:529–537. https://doi.org/10.1097/RLI.0b013e3181ea703d
Thilmann O, Larsson EM, Bjorkman-Burtscher IM, Stahlberg F, Wirestam R (2005) Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3T. J Magn Reson Imaging 22:597–604. https://doi.org/10.1002/jmri.20420
Kopka L, Vosshenrich R, Rodenwaldt J et al (1998) Differences in injection rates on contrast-enhanced breath-hold three-dimensional MR angiography. Am J Roentgenol 170:345–348. https://doi.org/10.2214/ajr.170.2.9456943
Kramer H, Michaely HJ, Requardt M et al (2007) Effects of injection rate and dose on image quality in time-resolved magnetic resonance angiography (MRA) by using 1.0M contrast agents. Eur Radiol 17:1394–1402
Madsen MT (1992) A simplified formulation of the gamma variate function. Phys. Med Biol 37:1597–1600
Crisi G, Filice S, Erb G, Bozzetti F (2017) Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas. J Magn Reson Imaging 45:500–506. https://doi.org/10.1002/jmri.25370
Yamada M, Taoka T, Kawaguchi A et al (2019) Inter-individual comparison of gadobutrol and gadoteridol tissue time-intensity profiles for dynamic susceptibility contrast perfusion MR imaging. Magn Reson Med Sci 18:75–81. https://doi.org/10.2463/mrms.mp.2017-0172
ACR–ASNR–SPR practice parameter for the performance of intracranial magnetic resonance perfusion imaging. Revised 2017 Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Perfusion.pdf
Wintermark M, Sesay M, Barbier E et al (2005) Comparative overview of brain perfusion imaging techniques. Stroke 36:e83–e99. https://doi.org/10.1161/01.STR.0000177884.72657.8b
Maravilla KR, Smith MP, Vymazal J et al (2015) Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study). AJNR 36(1):14–23. https://doi.org/10.3174/ajnr.A4154
Shen Y, Goerner FL, Snyder C, et al. (2015) T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol. 50(5):330–8. https://doi.org/10.1097/RLI.0000000000000132
Funding
No funding was received for this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Panara, V., Chiacchiaretta, P., Rapino, M. et al. Dynamic susceptibility MR perfusion imaging of the brain: not a question of contrast agent molarity. Neuroradiology 64, 685–692 (2022). https://doi.org/10.1007/s00234-021-02807-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00234-021-02807-7